CLAIM AMENDMENTS

1. (currently amended): An immunogenic composition for eliciting an immune response to a pathogenic organism which composition comprises a recombinant protein [[and]] conjugated to a polysaccharide component, wherein said protein comprises the toxin A repeating units (rARU) of Clostridium difficile and said polysaccharide component is characteristic an antigen of a pathogenic microorganism, which pathogenic microorganism is other than C. difficile,

wherein said composition is formulated for injection.

- 2. (canceled)
- 3. (original): The immunogenic composition of claim 1, wherein said polysaccharide component is a capsular polysaccharide or a lipopolysaccharide.
 - 4-5. (canceled)
- 6. (previously presented): The immunogenic composition of claim 1, wherein said protein is a fusion protein.
 - 7-12. (canceled)
- 13. (previously presented): The immunogenic composition of claim 1, wherein said immune response comprises a cellular immune response.
- 14. (previously presented): The immunogenic composition of claim 1, wherein said immune response comprises a humoral immune response.
- 15. (previously presented): The immunogenic composition of claim 1, wherein said immune response is protective against said pathogenic microorganism.
 - 16-18. (canceled)

- 19. (previously presented): The immunogenic composition of claim 1, wherein said polysaccharide has been isolated from said pathogenic microorganism.
- 20. (previously presented): The immunogenic composition of claim 1, wherein said pathogenic microorganism is selected from the group consisting of: *Streptococcus pneumoniae*; *Neisseria meningitidis*; *Escherichia coli*; and *Shigella*.

21-22. (canceled)

- 23. (previously presented): The immunogenic composition of claim 20, wherein said pathogenic microorganism is *Streptococcus pneumoniae*.
- 24. (previously presented): The immunogenic composition of claim 23, wherein said immune response is protective against *Streptococcus pneumoniae*.
- 25. (previously presented): The immunogenic composition of claim 20, wherein said pathogenic microorganism is *Shigella*.
- 26. (previously presented): The immunogenic composition of claim 25, wherein said immune response is protective against *Shigella*.

27. (canceled)

- 28. (previously presented): The immunogenic composition of claim 20, wherein said pathogenic microorganism is *Neisseria meningitidis*.
- 29. (previously presented): The immunogenic composition of claim 20, wherein said pathogenic microorganism is *Escherichia coli* K1.
- 30. (previously presented): The immunogenic composition of claim 1, wherein said pathogenic microorganism is selected from the group consisting of: *Staphylococcus aureus*;

coagulase-negative Staphylococcus; Enterococcus species; Enterobacter species; Candida species; and Pseudomonas species.

- 31. (previously presented): The immunogenic composition of claim 30, wherein said immune response is protective with respect to *Staphylococcus aureus*; coagulase-negative *Staphylococcus*; *Enterococcus* species; *Enterobacter* species; *Candida* species; or *Pseudomonas* species.
 - 32. (canceled)
- 33. (previously presented): The immunogenic composition of claim 30, wherein said pathogenic microorganism is *Staphylococcus aureus* serogroup 5 or serogroup 8.
 - 34-35. (canceled)
- 36. (previously presented): The immunogenic composition of claim 1 which further comprises a pharmaceutically acceptable carrier.
 - 37. (original): A vaccine comprising the immunogenic composition of claim 36.
- 38. (original): The vaccine of claim 37, wherein said vaccine is formulated for use in humans.
- 39. (original): The vaccine of claim 37, wherein said vaccine is formulated for use in animals.
 - 40-61. (canceled)
- 62. (previously presented): The immunogenic composition of claim 28, wherein said immune response is protective against *Neisseria meningitidis*.
 - 63. (canceled)

- 64. (withdrawn): A method to elicit an immune response in a subject to a pathogenic organism which method comprises injecting a subject in need of such response with an effective amount of the immunogenic composition of claim 1.
- 65. (withdrawn): A method to elicit an immune response in a subject to a pathogenic organism which method comprises injecting a subject in need of such response with an effective amount of the immunogenic composition of claim 36.
- 66. (withdrawn): A method to elicit an immune response in a subject to a pathogenic organism which method comprises injecting a subject in need of such response with an effective amount of the vaccine of claim 37.